United Therapeutics (UTHR) Tops Q2 EPS by 67c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $532.78 -2.24%
Revenue Growth %: -1.2%
Financial Fact:
Cost of product sales: 23.6M
Today's EPS Names:
PKE, BYRN, HELE, More
Revenue Growth %: -1.2%
Financial Fact:
Cost of product sales: 23.6M
Today's EPS Names:
PKE, BYRN, HELE, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $5.24, $0.67 better than the analyst estimate of $4.57. Revenue for the quarter came in at $596.5 million versus the consensus estimate of $524.18 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Humana soars, Alignment Healthcare sinks on Medicare rating changes
- UBS Downgrades Havells India (HAVL:IN) to Neutral
- United Therapeutics Corp. (UTHR) PT Raised to $708 at RBC Capital
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
